Pfizer to present new Xeljanz data at ACR/ARHP 2016

Pfizer has announced plans to present new clinical data on Xeljanz at the upcoming annual meeting of the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP).

A total of 20 abstracts detailing the performance of the Janus kinase inhibitor will be presented at the conference, including results from the two pivotal phase III OPAL studies, which are assessing Xeljanz in the treatment of psoriatic arthritis.

Xeljanz is the only Janus kinase inhibitor under investigation for psoriatic arthritis, with the OPAL Broaden data to be highlighted during a plenary session and the OPAL Beyond results presented during a late-breaking abstract poster session.

In addition, new and updated research assessing the drug in rheumatoid arthritis will be presented, offering fresh insights into its benefit/risk profile, safety, efficacy, time to response and performance with or without concomitant use of glucocorticoids.

Michael Corbo, chief development officer for inflammation and immunology at Pfizer's global product development business, said: "As part of our commitment to inflammation and immunology, we continue to advance our leading science in the research of Janus kinase inhibition."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.